Chen Yinhuai, Caldwell Julie M, Pereira Elizabeth, Baker Robert W, Sanchez Yolanda
Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755 and Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0524.
Department of Pharmacology and Toxicology, Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, New Hampshire 03755 and Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, Cincinnati, Ohio 45267-0524.
J Biol Chem. 2009 Jan 2;284(1):182-190. doi: 10.1074/jbc.M806530200. Epub 2008 Nov 4.
The conserved protein kinase Chk1 is a player in the defense against DNA damage and replication blocks. The current model is that after DNA damage or replication blocks, ATR(Mec1) phosphorylates Chk1 on the non-catalytic C-terminal domain. However, the mechanism of activation of Chk1 and the function of the Chk1 C terminus in vivo remains largely unknown. In this study we used an in vivo assay to examine the role of the C terminus of Chk1 in the response to DNA damage and replication blocks. The conserved ATR(Mec1) phosphorylation sites were essential for the checkpoint response to DNA damage and replication blocks in vivo; that is, that mutation of the sites caused lethality when DNA replication was stalled by hydroxyurea. Despite this, loss of the ATR(Mec1) phosphorylation sites did not change the kinase activity of Chk1 in vitro. Furthermore, a single amino acid substitution at an invariant leucine in a conserved domain of the non-catalytic C terminus restored viability to cells expressing the ATR(Mec1) phosphorylation site-mutated protein and relieved the requirement of an upstream mediator for Chk1 activation. Our findings show that a single amino acid substitution in the C terminus, which could lead to an allosteric change in Chk1, allows it to bypass the requirement of the conserved ATR(Mec1) phosphorylation sites for checkpoint function.
保守的蛋白激酶Chk1在抵御DNA损伤和复制阻滞过程中发挥作用。目前的模型认为,在DNA损伤或复制阻滞之后,ATR(Mec1)会在非催化性的C末端结构域上磷酸化Chk1。然而,Chk1的激活机制以及Chk1 C末端在体内的功能在很大程度上仍不清楚。在本研究中,我们使用体内试验来检测Chk1的C末端在应对DNA损伤和复制阻滞中的作用。保守的ATR(Mec1)磷酸化位点对于体内DNA损伤和复制阻滞的检查点反应至关重要;也就是说,当DNA复制被羟基脲阻滞时,这些位点的突变会导致细胞死亡。尽管如此,ATR(Mec1)磷酸化位点的缺失并没有改变Chk1在体外的激酶活性。此外,在非催化性C末端保守结构域中一个不变亮氨酸处的单个氨基酸替换,恢复了表达ATR(Mec1)磷酸化位点突变蛋白的细胞的活力,并解除了对Chk1激活的上游介质的需求。我们的研究结果表明,C末端的单个氨基酸替换可能导致Chk1的变构变化,使其能够绕过保守的ATR(Mec1)磷酸化位点对检查点功能的需求。